SCHEDULE: Beryl Capital Divests Entire Stake in 2seventy bio
Ownership Disclosure
Beryl Capital Management and its affiliates have reported a complete divestiture of their beneficial ownership in 2seventy bio, Inc., holding 0% of common stock.
Summary
- Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates that as of June 30, 2025, the reporting persons beneficially own 0.00 shares of 2seventy bio, Inc. Common Stock.
- This represents 0% of the class of securities.
- The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest therein.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the complete divestiture of shares by an institutional investor, which can be interpreted as a lack of confidence in the company's future prospects by that specific entity. However, it's a routine ownership disclosure and not indicative of operational issues.
Negatives
- Beryl Capital Management and its affiliates have fully divested their stake in 2seventy bio, Inc., indicating a complete exit from their investment.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding 2seventy bio, Inc.'s future performance or strategic direction.
Industry Context
This filing is a routine disclosure of an institutional investor's change in beneficial ownership. It does not provide insights into broader industry trends or competitive landscape, other than indicating a specific investor's decision to exit a position in a biotechnology company.
Stakeholder Impact
- Shareholders: The complete divestiture by Beryl Capital Management could be perceived negatively by other investors, potentially influencing sentiment or trading activity, though the direct impact is likely minimal given it's a disclosure of a past event.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (beneficial ownership dropped to 0%). |
| 07/31/2025 | Date the Schedule 13G Amendment No. 1 was signed by reporting persons. |
| 08/05/2025 | Date of the Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. |
Keywords
2seventy bio, Beryl Capital Management, Schedule 13G, Ownership Disclosure, Common Stock, Divestment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.